Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis

Blood

Volumn 99, Issue 12, 2002, Pages 4326-4335

  Thiede, Christian ^a,b   Steudel, Christine ^a,b   Mohr, Brigitte ^a,b   Schaich, Markus ^a,b   Schäkel, Ulrike ^a,b   Platzbecker, Uwe ^a,b   Wermke, Martin ^a,b   Bornhäuser, Martin ^a,b   Ritter, Markus ^a,b   Neubauer, Andreas ^a,b   Ehninger, Gerhard ^a,b   Illmer, Thomas ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CELL DNA; IMMUNOGLOBULIN F(AB) FRAGMENT; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 6; CHROMOSOME TRANSLOCATION 9; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GENE FREQUENCY; GENE MUTATION; GENETIC EPIDEMIOLOGY; HUMAN; HUMAN TISSUE; KARYOTYPING; MAJOR CLINICAL STUDY; MONOCYTE; MUTANT; MUTATION RATE; POINT MUTATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TANDEM REPEAT; WILD TYPE;

EID: 0037097716     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.12.4326     Document Type: Article

References (52)

1. Acute myeloid leukemia
2. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties
3. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene
4. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells
5. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations
6. FLT3: Receptor and ligand: Biology and potential clinical application
7. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells
8. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
9. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines
10. Expression of the flt3 receptor and its ligand on hematopoietic cells
11. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells
12. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
13. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: A study on a large series of patients and cell lines
14. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
15. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene
16. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
17. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia: The Children's Cancer and Leukemia Study Group, Japan
18. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children
19. Prevalence and prognostic significance of flt3 internal tandem duplication in pediatric acute myeloid leukemia
20. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
21. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
22. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the ras and STAT5 pathways
23. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia
24. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
25. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia
26. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: The European APL Group
27. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
28. Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: Results of a prospective investigation
29. Novel non-template nucleotide addition reactions catalyzed by procaryotic and eucaryotic DNA polymerases
30. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers
31. Analysis of gene amplification in archival tissue by differential polymerase chain reaction
32. Polymerase chain reaction based assay to detect allelic loss in human DNA: Loss of beta-interferon gene in chronic myelogenous leukemia
33. Physical linkage of the human growth hormone gene cluster and the skeletal muscle sodium channel alpha-subunit gene (SCN4A) on chromosome 17
34. Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping
35. Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome
36. Nonparametric estimation from incomplete observations
37. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase
38. Multilevel effects of flt3 ligand on human hematopoiesis: Expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors
39. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia: Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)
40. FLT3 Length mutations in AML: Correlation to cytogenetics, FAB-subtype, and prognosis in 652 patients
41. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study
42. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study
43. Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation
44. The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC 10 and 12 trials
45. Genetic instabilities in human cancers
46. Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis
47. The nucleoporin CAN/Nup214 binds to both the cytoplasmic and the nucleoplasmic sides of the nuclear pore complex in overexpressing cells
48. Expression cloning of multiple human cDNAs that complement the phenotypic defects of ataxia-telangiectasia group D fibroblasts
49. The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner
50. Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies
51. A role for PML and the nuclear body in genomic stability